Michael Norton Spector

US Patent:

20200330441, Oct 22, 2020

Filed:

Jul 7, 2020

Appl. No.:

16/922712

Inventors:

Michael Spector - Shamong NJ, US
- Pittsburgh PA, US

International Classification:

A61K 31/43
A61K 31/424
A61P 31/04
A61P 31/00
A61P 27/16
A61K 45/06

Abstract:

The invention is directed to a pediatric oral suspension composition containing amoxicillin and clavulanate potassium where the clavulanate potassium is present in an amount equal to or less than about 21.5 mg/5 mL, and a method of treating bacterial infections by providing between about one to about fourteen dosage days of the composition. Also disclosed are methods of treating a patient comprising administering amoxicillin and clavulanate potassium to the patient in dosages of at least about 80 mg/kg/day of the amoxicillin and from about 1.66 mg/kg/day to about 2.84 mg/kg/day of the clavulanate potassium. The methods are useful for treating pediatric otitis media, treating a drug resistant bacterial infection, or treating beta-lactamase producing or in a patient under 24 months of age.

US Patent:

20160339002, Nov 24, 2016

Filed:

Jan 10, 2013

Appl. No.:

14/371731

Inventors:

Michael Spector - Shamong NJ, US
Alejandro Hoberman - Wexford PA, US

International Classification:

A61K 31/43
A61K 9/00
A61K 31/424
A61K 9/10

Abstract:

The invention is directed to a pediatric oral suspension composition containing amoxicillin and clavulanate potassium where the clavulanate potassium is present in an amount equal to or less than about 21.5 mg/5 mL, and a method of treating bacterial infections by providing between about one to about fourteen dosage days of the composition.